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An investigation of factors predicting the
type of bladder antimuscarinics initiated in
Medicare nursing homes residents
Daniela C. Moga1*, Qishan Wu2, Pratik Doshi2 and Amie J. Goodin3
Abstract
Background: To examine factors predicting type of bladder antimuscarinics (BAM) initiated in nursing home
(NH) residents.
Methods: Incident BAM initiators following NH admission were identified by constructing a retrospective cohort from
Medicare files and Minimum Data Set (MDS). Participants included all residents 65 years and older admitted in Medicare-
certified NH between January 1, 2007 and December 31, 2008 who were prescribed BAM and had continuous Medicare
(Part A, B, and D) enrollment. Patient characteristics, medications, and comorbidities were derived from Medicare
enrollment and claims. NH characteristics and health status were derived from MDS assessments. The outcome
was defined as type of BAM initiated after admission (selective, non-selective extended release, non-selective
immediate release). Multinomial logistic regression using generalized estimating equation methodology determined
which factors predicted the type of BAM initiated.
Results: Twelve thousand eight hundred ninety-nine NH residents initiating BAM therapy were identified; 13.38% of
new users were prescribed selective BAM, 45.56% non-selective extended release, and 41.07% non-selective immediate
release medications. In both sexes, significant predictors of BAM included region of nursing home, body mass index,
cognitive performance score, frailty measures, activities of daily living, and measures of bladder continence. In women,
history of fracture and fall-related injuries were significant predictors of type of BAM use, while race and indicators of
balance were significant predictors of type of BAM use in men. Non-pharmacological continence management
strategies were not predictive of type of BAM initiation.
Conclusions: Several factors are important in predicting type of BAM initiation in both women and men, but
other factors are sex-specific. Some observed factors predicting the type of BAM initiated, such as other medications
use, body mass index, or provider-related factors are potentially modifiable and could be used in targeted interventions
to help optimize BAM use in this population.
Trial registration: Not applicable.
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Background
Urinary incontinence is defined as the involuntary loss
of urine [1], or the loss of urinary bladder control, and
includes stress, urgency and mixed incontinence [2]. Ur-
gency incontinence, which is the incontinence associated
with a strong desire to void, comprises the most com-
mon underlying type of urinary incontinence in older
persons. Prevalence estimates of urinary incontinence
range from 43 to 77%, making urinary incontinence one
of the most common conditions to affect nursing home
residents [3]. There are several negative consequences
for those living with this condition. Urinary incontinence
is associated with an increased risk of falls, fractures, or
bacterial infections [4]. Previous studies have shown that
urinary incontinence increased the number of hospitali-
zations by 30 to 50% [5], and negatively impacted quality
of life (QOL) in nursing home residents [6]. Addition-
ally, the economic costs associated with managing urin-
ary incontinence are significant [7, 8].
To date, available treatment options for urinary incon-
tinence result in various degrees of symptom manage-
ment, rather than a curative effect. Selecting the
appropriate urinary incontinence treatment strategy de-
pends on the type of incontinence, its severity and the
underlying cause, and often time, different non-
pharmacological and/or pharmacological options are
used in combination to provide the best symptom man-
agement for a particular patient. The available non-
pharmacological alternatives include behavioral therapies
(i.e., bladder training, double voiding, fluid consumption,
healthy lifestyle changes, or scheduled toilet trips, pelvic
floor muscle exercises), electrical stimulation, absorbent
pads and catheters, or surgical interventions [9–14].
Pharmacological interventions are available for urgency
and mixed incontinence, with bladder antimuscarinic
(BAM) drugs at the forefront, often time in addition to
behavioral strategies. These drugs have an antagonistic
effect on the muscarinic receptors in the bladder de-
trusor muscle that provide beneficial effects on urgency
or mixed urinary incontinence management [15, 16].
Clinical trials have shown the effectiveness of these
drugs in reducing incontinence episodes [17–23]; how-
ever, it should be noted that some of these trials were
conducted in younger populations or outside of the
long-term care environment, and findings may not be
generalizable to older patients living in nursing homes
[18–20]. In addition to the bladder muscarinic receptors,
the five different muscarinic receptors (M1–M5) [24]
are widespread throughout the body resulting in various
undesirable effects after BAM drugs, especially when
non-selective agents are initiated. Some of these effects
are bothersome and may be associated with treatment
discontinuation [25, 26]. Other adverse effects, such as
falls, fractures, or cognitive impairment, have been
associated with significant risks, including an increased
mortality [27–29]. To our understanding, there is lim-
ited information available on factors influencing BAM
therapy selection in the nursing home population and
previous investigations raised question on whether drug
therapy for urinary incontinence is optimally used in
long-term care [30]. It is important to understand these
factors given the non-curative effects and adverse event
potential of BAM, especially those factors that are modi-
fiable and could be targeted in future interventions
aimed to optimize medication use. Furthermore, gather-
ing information on factors associated with BAM initi-
ation would be important for future comparative
effectiveness studies by informing the selection of appro-
priate strategies for confounding control when using ob-
servational data. Additionally, there is evidence to
suggest that nonselective BAM agents may be associated
with stronger negative effects on cognitive function than
selective BAM agents [31–33], but controversy still ex-
ists whether all or only some BAM pose these potential
risks [34]. As many of the studies investigating the link
between BAM use and adverse events were conducted
with small samples, in community dwelling and/or
younger populations, these future studies are needed to
address the existing controversies regarding not only dif-
ferences in risks with different BAM, but also to estab-
lish the clinical evidence for the nursing homes
population. Therefore, the objective of this study was to
identify factors predicting the type of BAM initiated in
long-term care residents in Medicare nursing homes
throughout the US. In addition, considering the import-
ant sex-differences related to urinary incontinence
prevalence, symptomatology, and treatment seeking be-
havior, we also investigated whether there are differences
in predictors between women and men.
Methods
Data sources and study population
Study design and all of the analyses were conducted
based on an a priori specified protocol approved by the
Institutional Review Board at the University of Kentucky.
Due to the retrospective nature of the design, the Insti-
tutional Review Board granted the investigators a waiver
of informed consent. For this study we linked Medicare
claims data with Minimum Data Set (MDS) assessments.
The linked dataset contained enrollment information,
inpatient and pharmacy claims, and MDS assessment
data collected in between January 1, 2007 through
December 31, 2008. We included patients 65 years or
older who were continuously eligible for Medicare Part
A, B, and D, but no enrollment in a Health Maintenance
Organization (HMO) plan and were admitted to any of
the Medicaid and/or Medicare certified long-term care
facilities, all of which conduct MDS assessments. We
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also required an admission followed by a minimum of
one quarterly MDS assessment to ensure that only
long-term stays were included in the analyses [35]. If
a patient had more than one long term stay in a
nursing home during our study period, then only the
first stay was examined in this study. Figure 1 pro-
vides a detailed outline of the exclusion and inclusion
criteria for the study sample.
Patients who did not receive prescriptions for BAM at
any point in the study period were defined as “non BAM
users” and were excluded from the analysis. Those with
at least one pharmacy claim for any BAM (i.e., flavoxate,
hyoscyamine, oxybutynin, propantheline, tolterodine,
trospium, darifenacin, solifenacin) were considered BAM
users and were further categorized as incident, prevalent,
or former users (see Fig. 2). Non-selective immediate
release BAM formulations included: flavoxate, hyocya-
mine, oxybutnynin, propantheline, tolterodine, and tros-
pium. Non-selective extended release BAM formulations
included: oxybutynin, tolterodine, and trospium.
Selective BAM formulations included darifenacin and
solifenacin. Our analyses included only those identified
as incident (or new) users of a non-transdermal
formulation who did not have BAM therapy prior to
nursing home admission. Prevalent users were defined
as (1) those with a minimum of one pharmacy claim for
a BAM during their nursing home stay that also had at
least one claim before nursing home admission, or (2)
those with a pharmacy claim for BAM during their nurs-
ing home stay, but with insufficient medical history in
the dataset (i.e., 6 months), or (3) those with a pharmacy
claim for BAM during the first 3 days of their nursing
home stay, regardless of the history in the dataset [36].
Patients who had received a prescription for BAM at
any point in the claims data look-back period (from
January 1, 2007 until nursing home admission), but not
during nursing home stay were considered former users.
Patients who were prescribed BAM at least 3 days or
more following nursing home admission in the study
period, and also had a minimum of 6 months of medical
history in our dataset were defined as the “new user”
[36]. The date of the first pharmacy prescription claim
for a BAM was considered the index date for that per-
son. New BAM users were further sub-divided into three
categories based on muscarinic receptors’ selectivity and
formulation; specifically, we grouped them as selective
Fig. 1 Study Sample Selection: Flowchart of Inclusion/Exclusion Criteria
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BAM medications, and either extended release (ER)
non-selective BAM or immediate release (IR) non-
selective BAM. Additional file 1: Table S1 includes a list
of all BAM medications analyzed in this study, along
with a summary of their muscarinic effects, other im-
portant drug characteristics and their clinical relevance
[34, 37–45]. The last MDS assessment record prior to
the index date along with Medicare enrollment files and
medical and pharmacy claims in the 6 months period
preceding this date were used to determine baseline
characteristics used in the analysis.
Variables
The outcome of interest for the study was defined as the
type of BAM at initiation. For our analysis, the reference
category consisted of patients who were new users of
non-selective IR BAM. Potential predictors of type of
BAM initiation were identified from enrollment files,
claims, and from MDS assessments. The list of potential
predictors included (1) socio-demographic characteris-
tics (age at BAM initiation, sex, race, nursing home geo-
graphic region within one of the four major Census
tracts, body mass index [BMI]); (2) cognitive measures
(patient Cognitive Performance Score at BAM initiation)
[46, 47]; (3) functional measures (Changes in Health,
End-Stage Disease and Symptoms and Signs [CHESS]
score [48], Activities of Daily Living [ADL] [49], balance,
and gait performance); (4) bladder and bowel incontin-
ence measures; (5) measures of non-pharmacological
treatment for urinary incontinence (any scheduled toilet-
ing plan, indwelling catheter, or pads/briefs used); (6) co-
morbidities either identified based on the Elixhauser
algorithm [50] or from the last MDS assessment prior to
BAM initiation (hemiplegia/hemiparesis, quadriplegia,
aphasia, cerebral palsy, multiple sclerosis, Parkinson’s
disease, bipolar disorder, and schizophrenia); (7) anti-
cholinergic load measured using the anticholinergic drug
scale, with removal of BAM [51]; and (8) concomitant
medications, including: cognitive enhancers, antiparkin-
son medications, diuretics, antipsychotics, antivertigo
medications, beta blockers, anxiolytic sedatives, ACE in-
hibitors, antidepressants, ARBs, alpha blockers, anticon-
vulsants, vasodilators, and benzodiazepines. Table 1
contains a list of study variables with their respective
data sources.
Statistical analysis
Frequencies and descriptive statistics of patient charac-
teristics were calculated for the whole study sample of
new BAM users and for new users by type of BAM.
Multinomial logistic regression via generalized estimat-
ing equations (GEE) was employed to determine the fac-
tors predicting type of BAM initiation. Predictors were
selected for inclusion in the multivariable analysis using
a manual backward elimination procedure. After includ-
ing sex as potential predictor, we also conducted the
analyses using stratification by sex to determine whether
there were sex-specific differences in factors predicting
type of BAM at initiation.
Approximately 4.39% of the total study population’s
records contained at least one missing value, primarily
among CHESS scores and BMI. To address the potential
for bias, we conducted sensitivity analyses to determine
whether there were any differences in the type of BAM
uptake between those with complete information and
those with missing data. Specifically, we used imputation
techniques to assign that variable’s mode to the missing
value (e.g., if a patient record had a missing CHESS
score, the mode of the CHESS variable was imputed for
that patient record). Results of the model using the im-
puted data were compared to the original results to test
robustness of the original model.
Goodness of fit was assessed for each model via Pear-
son tests for overall fit and Likelihood Ratio tests for
Fig. 2 Defining New Bladder Antimuscarinics Users
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joint significance of all predictors. Validation for each
model was conducted by creating a confusion matrix
(aka cross classification table) using observed and pre-
dicted values calculated from the fitted models. The per-
cent match, meaning proportion of correctly classified
variables, was then reported for each model. All analysis
was conducted in SAS v9.4 [52].
Results
Treatment with BAM was initiated by 12,899 nursing
home residents; of these, 1726 (13.38%) were prescribed
selective BAM, 5876 (45.56%) were prescribed non-
selective ER BAM, and 5297 (41.07%) were prescribed
non-selective IR BAM. New BAM users groups were
similar in demographic characteristics such as age and
race (Table 2); however, fewer non-selective IR BAM
users were bowel continent when compared to non-
selective ER BAM users and selective BAM users. Also,
non-selective IR BAM users demonstrated less ability to
maintain balance while sitting when compared with
other BAM users. Lastly, there were geographic pre-
scribing differences among the types of BAM, with fewer
non-selective IR BAM among residents users in nursing
homes located in the Midwest region and a greater pro-
portion of IR BAM users in the northeast region.
Table 3 shows multivariate model results for the entire
cohort. Important factors predicting type of BAM initi-
ated included demographic characteristics as well as
medical conditions and treatments, and the use of non-
pharmacological interventions for bladder control (i.e.,
any scheduled toileting plan, indwelling catheter, or use
of pads/briefs). Some of these factors were also relevant
in the sex-stratified models (Table 4), but some were
only significant in the model based on the entire popula-
tion. For example, age group of aged 85 and older was
predictive of less non-selective IR BAM initiation in the
study population even though it was not found to be
predictive in the sex-stratified specifications. Black race
Table 1 Identification and Definition of Study Variables
Variable Group Data Source Identification and/or Definition
Socio-demographic Characteristics Enrollment Files, Claims,
Minimum Data Set
Patient age at BAM initiation, gender, race, nursing home geographic region,
calculated Body Mass Index (BMI)
Cognitive Performance Score [46, 47] Minimum Data Set Categories were collapsed as follows: Intact, Borderline Intact/Mild Impairment,
Moderate Impairment, Moderate-severe/Severe/Very Severe Impairment.
Behavioral Score [56] Minimum Data Set Total score includes sum of score of five items, where every item is measured on a
scale from 0 (behavior not present in past 7 days) to 3 (behavior is daily), with a
total score possibility between 0 and 15 points. The items include wandering (item
E4a), verbally abusive behavior (item E4b), physically abusive behavior (item E4c),
socially inappropriate or disruptive behavioral symptoms (item E4d), and resistance
to care (item E4e).
Changes in Health, End-Stage Disease
and Symptoms and Signs (CHESS) [48]
Minimum Data Set Categories were collapsed as follows: Score of 0, Score of 1 or 2, Score of 3, Score
of 4 or 5.
Activities of Daily Living [49] Minimum Data Set Total score range from 0 to 28.
Elixhauser Comorbidities [50] Minimum Data Set Diagnosis indicators for: congestive heart failure, cardiac arrhythmia, peripheral vascular
disorders, hypertension (uncomplicated and complicated), diabetes (uncomplicated and
complicated), renal failure, AIDS/HIV, weight loss, paralysis, other neurological disorders,
psychoses, depression, blood loss anemia.
Other Comorbidities Minimum Data Set,
Claims
Diagnosis of: hemiplegia/hemiparesis, paraplegia, quadriplegia, aphasia, cerebral palsy,
multiple sclerosis, Parkinson’s disease, manic depression/bipolar disease, schizophrenia.
Continence-Related Measures Minimum Data Set Bladder continence (item H1B), bowel continence (item H1A), bowel elimination
patterns (items H2A, H2B, H2C, H2D), continence management (scheduled toileting
plan [item H3A], bladder retraining program [item H3B], external catheter [item H3C],
indwelling catheter [item H3D], intermittent catheter [item H3E], pads/briefs used [item
H3G], no appliance or program [item H3J]).
Infection Minimum Data Set Diagnosis of urinary tract infection in last 30 days (item I2J).
Balance and Gait Minimum Data Set Balance while standing (item G3A), balance while sitting (item G3B), unsteady gait
(item J1 N), fell in past 30 days (item J4A), fell in past 31–180 days (item J4B), hip
fracture in last 180 days (item J4C), other fracture in last 180 days (item J4D).
Total Medications and Concomitant
Medications
Claims Total number of medications were counted for last 7 days and categorized as: 0
medications, 1 to 5, 6 to 10, or >10 medications. Concomitant medication classes
included: calcium channel blockers, cognitive enhancers, antiparkinson, diuretics,
antipsychotics, antivertigo, beta blockers, anxiolytic sedative/hypnotics, ACE
inhibitors, antidepressants, ARB, alpha blockers, anticonvulsant, vasodilators,
benzodiazepines.
Anticholinergic Burden/ADS Score [51] Claims Calculated from concomitant medications after removal of prescribed BAM medications.
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Table 2 Study Sample Characteristics at Baseline
New Non-Selective IR
Users (n = 5297)
New Non-Selective ER






65–74 942 (17.8%) 1046 (17.8%) 309 (17.9%) 2297 (17.8%)
75–84 1959 (37.0%) 2318 (39.4%) 651 (37.7%) 4928 (38.2%)
85 and Older 2396 (45.2%) 2512 (42.8%) 766 (44.4%) 5674 (44.0%)
Sex
Female 3793 (71.6%) 4624 (78.7%) 1315 (76.2%) 9732 (75.4%)
Male 1504 (28.4%) 1252 (21.3%) 411 (23.8%) 3167 (24.6%)
Race
White 4669 (88.1%) 5278 (89.8%) 1561 (90.4%) 11,508 (89.2%)
Black 459 (8.7%) 427 (7.3%) 115 (6.7%) 1001 (7.8%)
Other 169 (3.2%) 171 (2.9%) 50 (2.9%) 390 (3.0%)
Nursing Home Region
Midwest 1744 (32.9%) 2695 (45.9%) 744 (43.1%) 5183 (40.2%)
Northeast 1500 (28.3%) 1168 (19.9%) 285 (16.5%) 2953 (22.9%)
South 1705 (32.2%) 1615 (27.5%) 613 (35.5%) 3933 (30.5%)
West 348 (6.6%) 398 (6.8%) 84 (4.9%) 830 (6.4%)
Body Mass Index
Underweight 573 (10.9%) 422 (7.2%) 100 (5.8%) 1095 (8.5%)
Normal 2304 (43.9%) 2322 (39.7%) 674 (39.3%) 5300 (41.4%)
Overweight 1357 (25.8%) 1614 (27.6%) 515 (30.0%) 3486 (27.2%)
Obese 1018 (19.4%) 1487 (25.4%) 428 (24.9%) 2933 (22.9%)
Cognitive Performance Score
Intact 978 (18.5%) 1355 (23.1%) 384 (22.3%) 2717 (21.1%)
Borderline intact/Mild impairment 1661 (31.4%) 2286 (39.0%) 698 (40.5%) 4645 (36.1%)
Moderate impairment 1598 (30.2%) 1826 (31.1%) 523 (30.3%) 3947 (30.7%)
Moderate-severe/Severe/Very Severe
impairment
1046 (19.8%) 402 (6.8%) 119 (6.9%) 1567 (12.2%)
Mean Behavioral Score (SD) 0.6 (1.42) 0.4 (1.15) 0.4 (1.12) 0.5 (1.27)
CHESS
Score of 0 1397 (27.5%) 1761 (30.9%) 560 (33.6%) 3718 (29.9%)
Score of 1 or 2 2984 (58.7%) 3418 (60.0%) 943 (56.6%) 7345 (59.0%)
Score of 3 552 (10.9%) 432 (7.6%) 133 (8.0%) 1117 (9.0%)
Score of 4 or 5 152 (3.0%) 85 (1.5%) 30 (1.8%) 267 (2.1%)
Mean Activities of Daily Living (SD) 17 (7.13) 14.5 (6.59) 14.0 (16.7) 15.5 (6.95)
Elixhauser Comorbidities
Congestive Heart Failure 1291 (24.4%) 1204 (20.5%) 352 (20.4%) 2847 (22.1%)
Cardiac Arrhythmia 1233 (23.3%) 1223 (20.8%) 345 (20.0%) 2801 (21.7%)
Peripheral Vascular Disorders 388 (7.3%) 434 (7.4%) 114 (6.6%) 936 (7.3%)
Hypertension, Uncomplicated 2227 (42.0%) 2723 (46.3%) 744 (43.1%) 5694 (44.1%)
Hypertension, Complicated 563 (10.6%) 519 (8.8%) 164 (9.5%) 1246 (9.7%)
Diabetes, Uncomplicated 1130 (21.3%) 1215 (20.7%) 346 (20.0%) 2691 (20.9%)
Diabetes, Complicated 290 (5.5%) 323 (5.5%) 78 (4.5%) 691 (5.4%)
Renal Failure 669 (12.6%) 572 (9.7%) 192 (11.1%) 1433 (11.1%)
AIDS/HIV 1 (0.0%) 1 (0.0%) 1 (0.1%) 3 (0.0%)
Moga et al. BMC Geriatrics  (2017) 17:295 Page 6 of 20
Table 2 Study Sample Characteristics at Baseline (Continued)
New Non-Selective IR
Users (n = 5297)
New Non-Selective ER





Weight Loss 504 (9.5%) 311 (5.3%) 87 (5.0%) 902 (7.0%)
Paralysis 225 (4.2%) 220 (3.7%) 49 (2.8%) 494 (3.8%)
Other Neurological Disorders 733 (13.8%) 648 (11.0%) 189 (11.0%) 1570 (12.2%)
Psychoses 281 (5.3%) 314 (5.3%) 86 (5.0%) 681 (5.3%)
Depression 835 (15.8%) 968 (16.5%) 300 (17.4%) 2103 (16.3%)
Blood Loss Anemia 114 (2.2%) 123 (2.1%) 29 (1.7%) 266 (2.1%)
Other Comorbidities
Hemiplegia/hemiparesis 451 (8.5%) 420 (7.1%) 111 (6.4%) 982 (7.6%)
Paraplegia 24 (0.5%) 25 (0.4%) 8 (0.5%) 57 (0.4%)
Quadriplegia 21 (0.4%) 8 (0.1%) 1 (0.1%) 30 (0.2%)
Aphasia 243 (4.6%) 96 (1.6%) 26 (1.5%) 365 (2.8%)
Cerebral Palsy 11 (0.2%) 7 (0.1%) 1 (0.1%) 19 (0.1%)
Multiple Sclerosis 31 (0.6%) 32 (0.5%) 12 (0.7%) 75 (0.6%)
Parkinsons Disease 399 (7.5%) 389 (6.6%) 143 (8.3%) 931 (7.2%)
Manic Depression/Bipolar Disease 128 (2.4%) 162 (2.8%) 39 (2.3%) 329 (2.6%)
Schizophrenia 121 (2.3%) 129 (2.2%) 40 (2.3%) 290 (2.2%)
Bladder Continence
Continent 2172 (41.0%) 2431 (41.4%) 706 (40.9%) 5309 (41.2%)
Usually Continent 515 (9.7%) 748 (12.7%) 211 (12.2%) 1474 (11.4%)
Occasionally Incontinent 521 (9.8%) 873 (14.9%) 248 (14.4%) 1642 (12.7%)
Frequently Incontinent 918 (17.3%) 1221 (20.8%) 364 (21.1%) 2503 (19.4%)
Incontinent 1170 (22.1%) 603 (10.3%) 197 (11.4%) 1970 (15.3%)
Bladder Continence Management
Scheduled Toileting Plan 1369 (25.8%) 1616 (27.5%) 448 (26.0%) 3433 (26.6%)
Bladder Retaining Program 58 (1.1%) 70 (1.2%) 12 (0.7%) 140 (1.1%)
External Catheter 11 (0.2%) 11 (0.2%) 1 (0.1%) 23 (0.2%)
Indwelling Catheter 1133 (21.4%) 855 (14.6%) 221 (12.8%) 2209 (17.1%)
Intermittent Catheter 57 (1.1%) 58 (1.0%) 20 (1.2%) 135 (1.0%)
Pads/Briefs Used 3376 (63.7%) 3306 (56.3%) 1002 (58.1%) 7684 (59.6%)
No Appliance or Program 1172 (22.1%) 1755 (29.9%) 496 (28.7%) 3423 (26.5%)
Bowel Continence
Continent 2544 (48.1%) 3821 (65.0%) 1113 (64.5%) 7478 (58.0%)
Usually Continent 461 (8.7%) 520 (8.9%) 185 (10.7%) 1166 (9.0%)
Occasionally Incontinent 307 (5.8%) 393 (6.7%) 100 (5.8%) 800 (6.2%)
Frequently Incontinent 565 (10.7%) 494 (8.4%) 134 (7.8%) 1193 (9.3%)
Incontinent 1417 (26.8%) 647 (11.0%) 194 (11.2%) 2258 (17.5%)
Bowel Elimination Patterns
Regular 4154 (78.4%) 45,98 (78.3%) 1342 (77.8%) 10,094 (78.3%)
Constipation 494 (9.3%) 557 (9.5%) 166 (9.6%) 1217 (9.4%)
Diarrhea 277 (5.2%) 228 (3.9%) 70 (4.1%) 575 (4.5%)
Fecal Impaction 4 (0.1%) 3 (0.1%) 2 (0.1%) 9 (0.1%)
Urinary Tract Infection in Last 30 Days 1210 (22.8%) 1285 (21.9%) 384 (22.2%) 2879 (22.3%)
Vision
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Table 2 Study Sample Characteristics at Baseline (Continued)
New Non-Selective IR
Users (n = 5297)
New Non-Selective ER





Adequate 3588 (68.2%) 4196 (71.5%) 1240 (71.8%) 9024 (70.2%)
Impaired 935 (17.8%) 1074 (18.3%) 314 (18.2%) 2323 (18.1%)
Moderately Impaired 330 (6.3%) 347 (5.9%) 97 (5.6%) 774 (6.0%)
Highly Impaired 318 (6.0%) 172 (2.9%) 51 (3.0%) 541 (4.2%)
Severely Impaired 93 (1.8%) 81 (1.4%) 24 (1.4%) 198 (1.5%)
Balance While Standing
Maintained position as required in test 256 (4.9%) 403 (6.9%) 134 (7.8%) 793 (6.2%)
Unsteady, but able to rebalance self
without physical support
709 (13.5%) 928 (15.9%) 290 (16.9%) 1927 (15.0%)
Partial physical support during test
or stands but does not follow
directions for test
1235 (23.5%) 1668 (28.5%) 517 (30.0%) 3420 (26.7%)
Not able to attempt test without
physical help
3052 (58.1%) 2845 (48.7%) 780 (45.3%) 6677 (52.1%)
Balance While Sitting
Maintained position as required in test 2846 (53.9%) 3857 (65.8%) 1188 (68.9%) 7891 (61.3%)
Unsteady, but able to rebalance
self without physical support
665 (12.6%) 773 (13.2%) 212 (12.3%) 1650 (12.8%)
Partial physical support during test
or stands but does not follow
directions for test
873 (16.5%) 767 (13.1%) 205 (11.9%) 1845 (14.3%)
Not able to attempt test without
physical help
897 (17.0%) 469 (8.0%) 120 (7.0%) 1486 (11.5%)
Unsteady Gait
Unsteady Gait 2459 (46.4%) 3192 (54.3%) 911 (52.8%) 6562 (50.9%)
Fell in past 30 days 1580 (29.8%) 2080 (35.4%) 559 (32.4%) 4219 (32.7%)
Fell in past 31–180 days 1320 (24.9%) 1548 (26.4%) 471 (27.3%) 3339 (25.9%)
Hip fracture in last 180 days 304 (5.7%) 421 (7.2%) 92 (5.3%) 817 (6.3%)
Other fracture in last 180 days 346 (6.5%) 533 (9.1%) 154 (8.9%) 1033 (8.0%)
Number of meds in the last 7 days
0 medications 9 (0.2%) 7 (0.1%) 1 (0.1%) 17 (0.1%)
1 to 5 medications 375 (7.1%) 376 (6.4%) 104 (6.0%) 855 (6.6%)
6 to 10 medications 1740 (32.8%) 1977 (33.7%) 580 (33.6%) 4297 (33.3%)
>10 medications 3.173 (59.9%) 3515 (59.8%) 1041 (60.3%) 7729 (59.9%)
Concomitant Medications
Calcium Channel Blockers 1319 (24.9%) 16,26 (27.7%) 507 (29.4%) 3452 (26.8%)
Cognitive Enhancers 1449 (27.4%) 1576 (26.8%) 509 (29.5%) 3534 (27.4%)
Antiparkinson 536 (10.1%) 585 (10.0%) 208 (12.1%) 1329 (10.3%)
Diuretics 2378 (44.9%) 2722 (46.3%) 811 (47.0%) 5911 (45.8%)
Antipsychotics 1510 (28.5%) 1277 (21.7%) 363 (21.0%) 3150 (24.4%)
Antivertigo 1164 (22.0%) 769 (13.1%) 210 (12.2%) 2143 (16.6%)
Beta Blockers 2296 (43.3%) 2497 (42.5%) 778 (45.1%) 5571 (43.2%)
Anxiolytic Sedative/Hypnotic Agent 795 (15.0%) 892 (15.2%) 250 (14.5%) 1937 (15.0%)
ACE Inhibitors 1521 (28.7%) 1855 (31.6%) 538 (31.2%) 3914 (30.3%)
Antidepressant 3019 (57.0%) 3319 (56.5%) 1004 (58.2%) 7342 (56.9%)
ARB 506 (9.6%) 653 (11.1%) 244 (14.1%) 1403 (10.9%)
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and balance while sitting were found to be significant
(black race was associated with more non-selective IR
BAM initiation; balance while sitting recorded as “Not
able to attempt test without physical help” was associ-
ated with less non-selective IR BAM initiation) in the
combined model though these were not significant in
the female-only specification. The absence of non-
pharmacological continence management strategies (i.e.,
use of pads/briefs, indwelling catheter) were found to be
significant predictors of more non-selective ER BAM ini-
tiation in the combined model specification. Anticholin-
ergic burden (ADS score) was found to be a significant
predictor of non-selective ER (relative to non-selective
IR) and non-selective IR (relative to selective) BAM initi-
ation in each model specification.
Table 4 shows the results of the multivariate models,
stratified by sex. Region of nursing home, BMI, cognitive
performance score, CHESS, ADLs, and bladder contin-
ence were significant predictors of BAM in both sexes.
Age and number of medications were not a significant
factor in type of new BAM use in either sex. A history
of fractures and fall-related injuries were significant pre-
dictors of type of BAM use in females (specifically, un-
steady gait, hip fracture in last 180 days, and other
fracture in last 180 days, all of which were associated
with more non-selective ER relative to non-selective IR),
but not in males. However, indicators of balance issues
were significant predictors of less non-selective ER rela-
tive to non-selective IR BAM use in males. Fewer co-
morbidities and concomitant medications were signifi-
cant predictors of type of BAM use in males when com-
pared to females. Significant predicting comorbidities in
females included aphasia (less non-selective IR), congest-
ive heart failure (less non-selective IR), hypertension
(uncomplicated; more non-selective IR), weight loss
(more non-selective IR), and blood loss anemia (less
non-selective IR), and none of these were predictors in
males. Hemiplegia/hemiparesis (more non-selective IR)
as well as diabetes (complicated; less non-selective IR)
were significant in males, but not in females. All signifi-
cant predicting concomitant medications were found in
both females and in males with the exception of calcium
channel blockers, cognitive enhancers, and ARB, which
were not found to be significant predictors in males.
Interestingly, race played a predictive role in type of
BAM initiation in males (less non-selective IR), but not
in females.
Sensitivity analyses
A specification using imputed values for the full model
with no stratification by sex was analyzed to further test
sensitivity (see Table 5). When imputed values were used
for the full model specification, estimates for race, bal-
ance while sitting, and aphasia were found to be some-
what different from estimates calculated without
imputation. In the full specification, fracture injuries
(hip and other) were associated with smaller estimates
as predictors of type of BAM initiation. Unlike the speci-
fications where sex was stratified, the full model specifi-
cation did not result in larger estimate sizes for non-
pharmacological continence management variables.
Overall, the similarity of results between the original
model and sensitivity analyses using imputed values sug-
gests that the original model is robust.
Sensitivity analysis using imputed values revealed simi-
lar results for both the female and male model specifica-
tions (see Table 6). However, when imputed values were
used estimates for type of BAM initiation were found to
be smaller for each of the following predictor variables:
race, aphasia (in females), hemiplegia/hemiparesis (in
males), diabetes (in males), urinary tract infection, bal-
ance while sitting, fell in past 30 days (in females), anti-
Parkinson’s medications, anti-vertigo medications, anti-
depressants, and benzodiazepines. Conversely, non-
pharmacological approaches to incontinence manage-
ment were found to yield larger estimates on type of
BAM initiation when imputed values were used. Specif-
ically, estimates were larger for use of pads or briefs as
well as regular bowel elimination patterns.
Pearson tests were significant for both female and male
models without imputation (p = 0.035 and p = 0.004, re-
spectively) and with imputation (p = 0.034 and p = 0.002,
respectively), which indicated good model fit. Likelihood
ratio tests were also significant for both female and male
models without imputation (p < 0.001 and p < 0.001, re-
spectively) and with imputation (p < 0.001 and p < 0.001,
respectively), which indicated joint significance of predic-
tors for each model. The validation procedure for the
Table 2 Study Sample Characteristics at Baseline (Continued)
New Non-Selective IR
Users (n = 5297)
New Non-Selective ER





Alpha Blockers 758 (14.3%) 822 (14.0%) 286 (16.6%) 1866 (14.5%)
Anticonvulsant 1336 (25.2%) 1263 (21.5%) 411 (23.8%) 3010 (23.3%)
Vasodilators 815 (15.4%) 734 (12.5%) 234 (13.6%) 1783 (13.8%)
Benzodiazepines 45 (0.8%) 49 (0.8%) 15 (0.9%) 109 (0.8%)
Mean Anticholinergic Burden/ADS Score (SD) 2.8 (2.45) 4.2 (2.46) 2.1 (2.00) 3.3 (2.53)
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Table 3 Predictors of Type of Bladder Antimuscarinics Initiation in All New Users (n = 12,251)
New non-selective ER user vs. new
non-selective IR user
New selective user vs. New
non-selective IR user
OR (95% CI) OR (95% CI)
Age Group
65 to 74 Ref. Ref.
75 to 84 1.044 (0.919–1.186) 0.982 (0.826–1.167)
85 and Older 0.857 (0.752–0.977)a 0.888 (0.743–1.060)
Female 1.266 (1.130–1.418)a 1.321 (1.132–1.541)a
Race
White Ref. Ref.
Black 1.288 (1.089–1.523)a 0.894 (0.703–1.137)
Other Race 1.062 (0.818–1.380) 1.353 (0.952–1.923)
Nursing Home Region
Midwest Ref. Ref.
Northeast 0.624 (0.557–0.700)a 0.562 (0.476–0.664)a
South 0.647 (0.581–0.719)a 1.052 (0.917–1.207)
West 0.848 (0.708–1.016) 0.622 (0.474–0.815)a
Body Mass Index
Underweight 0.779 (0.663–0.916)a 0.673 (0.527–0.859)a
Normal Ref. Ref.
Overweight 1.080 (0.971–1.202) 1.181 (1.024–1.362)a
Obese 1.346 (1.196–1.515)a 1.319 (1.124–1.547)a
Cognitive Performance Score
Intact Ref. Ref.
Borderline intact/Mild Impairment 1.009 (0.895–1.137) 1.057 (0.900–1.240)
Moderate impairment 1.011 (0.886–1.154) 0.937 (0.783–1.120)
Moderate-severe/Severe/Very Severe impairment 0.549 (0.456–0.659)a 0.512 (0.391–0.669)a
CHESS
Score of 0 Ref. Ref.
Score of 1 or 2 0.940 (0.849–1.040) 0.853 (0.745–0.977)a
Score of 3 0.727 (0.612–0.864)a 0.837 (0.663–1.057)
Score of 4 or 5 0.685 (0.498–0.943)a 0.835 (0.538–1.295)
Activities of Daily Living 0.989 (0.980–0.997)a 0.976 (0.965–0.988)a
Elixhauser/Other Comorbidities
Aphasia 0.554 (0.411–0.746)a 0.616 (0.399–0.951)a
Congestive Heart Failure 0.831 (0.745–0.927)a 0.834 (0.716–0.971)a
Hypertension, Uncomplicated 1.282 (1.170–1.406)a 1.037 (0.915–1.176)
Weight Loss 0.777 (0.652–0.926)a 0.772 (0.596–0.999)a
Bladder Continence
Continent Ref. Ref.
Usually Continent 1.235 (1.064–1.433)a 1.076 (0.880–1.316)
Occasionally Incontinent 1.575 (1.355–1.830)a 1.495 (1.224–1.827)a
Frequently Incontinent 1.524 (1.326–1.751)a 1.503 (1.246–1.813)a
Incontinent 1.083 (0.909–1.290) 1.204 (0.936–1.550)
No Bladder Continence Appliance or Program 1.217 (1.081–1.371)a 0.982 (0.836–1.153)
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model containing only females resulted in correct classifi-
cation of 61.08% observations, meaning a majority match
between predicted and observed values, and the validation
procedure conducted on the model containing only males
resulted in a correct classification of 64.34% observations.
Discussion
To our knowledge, this was the first study to investigate
factors associate with BAM initiation and to evaluate sex
differences in BAM initiation based on receptor selectivity.
In addition to informing the design of future comparative
effectiveness studies of different BAM, our findings are
clinically relevant for at least two reasons: first, the evi-
dence that BAM type (i.e., selectivity) is associated with
differential effects on cognitive function, and second, there
are sex differences in prevalence and symptomatology of
urinary incontinence. Specifically, these findings indicated
that fall-related injuries were significant predictors of type
of BAM initiation in females, while measures of balance
were found to be significant predictors of type of BAM
initiation in males. No non-pharmacological continence
management strategy (i.e., use of pads/briefs, indwelling
Table 3 Predictors of Type of Bladder Antimuscarinics Initiation in All New Users (n = 12,251) (Continued)
New non-selective ER user vs. new
non-selective IR user
New selective user vs. New
non-selective IR user
OR (95% CI) OR (95% CI)
Bowel Continence
Continent Ref. Ref.
Usually Continent 0.741 (0.632–0.869)a 0.936 (0.763–1.150)
Occasionally Incontinent 0.938 (0.775–1.135) 0.802 (0.617–1.042)
Frequently Incontinent 0.759 (0.641–0.899)a 0.626 (0.493–0.795)a
Incontinent 0.688 (0.573–0.826)a 0.582 (0.446–0.758)a
Urinary Tract Infection in Last 30 Days 1.119 (1.006–1.244)a 1.197 (1.037–1.382)a
Gait
Unsteady Gait 1.140 (1.042–1.246)a 1.017 (0.900–1.148)
Fell in Past 30 days 1.193 (1.082–1.315)a 1.072 (0.939–1.223)
Hip Fracture in Last 180 Days 1.254 (1.047–1.502)a 1.025 (0.778–1.333)
Other Fracture in Last 180 Days 1.249 (1.060–1.472)a 1.344 (1.071–1.662)a
Balance While Sitting
Maintained position as required in test Ref. Ref.
Unsteady, but able to rebalance self without physical support 1.043 (0.911–1.193) 0.958 (0.796–1.152)
Partial physical support during test or stands but does not follow
directions for test
1.026 (0.896–1.174) 0.866 (0.715–1.049)
Not able to attempt test without physical help 0.883 (0.709–0.980)a 0.700 (0.551–0.890)a
Concomitant Medications
Calcium Channel Blockers 1.014 (0.919–1.120) 1.182 (1.036–1.349)a
Cognitive Enhancers 1.031 (0.929–1.144) 1.203 (1.047–1.382)a
Antiparkinson 0.896 (0.774–1.038) 1.372 (1.139–1.653)a
Antipsychotics 0.476 (0.425–0.532)a 0.874 (0.751–1.017)
Antivertigo 0.269 (0.236–0.307)a 0.727 (0.608–0.869)a
Anxiolytic Sedative or Hypnotic Agent 0.672 (0.591–0.763)a 1.015 (0.853–1.208)
Antidepressant 0.597 (0.543–0.656)a 1.315 (1.157–1.494)a
ARB 1.024 (0.889–1.180) 1.287 (1.077–1.538)a
Alpha Blockers 1.024 (0.894–1.173) 1.299 (1.088–1.553)a
Anticonvulsant 0.719 (0.646–0.799)a 0.935 (0.812–1.076)
Vasodilators 0.595 (0.523–0.676)a 1.024 (0.861–1.216)
Benzodiazepines 2.249 (1.357–3.727)a 1.694 (0.860–3.338)
Anticholinergic Burden Score 1.476 (1.443–1.510)a 0.808 (0.780–0.836)a
aIndicates statistical significance
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Table 4 Predictors of Type of Bladder Antimuscarinics Initiation, Stratified by Sex
Females (n = 9322) Males (n = 3011)
New non-selective ER user
vs. new non-selective IR
user




user vs. new non-
selective IR user
New selective user vs.
New non-selective IR
user
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Race
White – – Ref. Ref.
Black – – 1.771 (1.319–2.379)a 1.085 (0.708–1.664)
Other Race – – 1.092 (0.685–1.742) 1.930 (1.086–3.430)a
Nursing Home Region
Midwest Ref. Ref. Ref. Ref.
Northeast 0.687 (0.603–0.782)a 0.607 (0.503–0.734)a 0.419 (0.329–0.534)a 0.422 (0.295–0.605)a
South 0.709 (0.629–0.799)a 1.074 (0.917–1.257) 0.528 (0.420–0.664)a 1.094 (0.823–1.453)
West 0.849 (0.689–1.047) 0.686 (0.501–0.940)a 0.886 (0.628–1.250) 0.550 (0.328–0.923)a
Body Mass Index
Underweight 0.769 (0.643–0.919)a 0.700 (0.537–0.913)a 0.846 (0.583–1.227) 0.498 (0.262–0.949)a
Normal Ref. Ref. Ref. Ref.
Overweight 1.122 (0.992–1.269) 1.151 (0.974–1.359) 0.982 (0.791–1.218) 1.413 (1.065–1.876)a
Obese 1.402 (1.229–1.598)a 1.284 (1.073–1.537)a 1.398 (1.085–1.801)a 1.739 (1.251–2.418)a
Cognitive Performance Score
Intact Ref. Ref. Ref. Ref.
Borderline intact/Mild Impairment 1.005 (0.878–1.150) 1.024 (0.854–1.228) 0.968 (0.747–1.255) 1.103 (0.782–1.558)
Moderate impairment 0.991 (0.853–1.150) 0.884 (0.722–1.084) 1.018 (0.772–1.342) 1.073 (0.740–1.556)
Moderate-severe/Severe/Very Severe
impairment
0.523 (0.424–0.645)a 0.424 (0.310–0.579)a 0.519 (0.361–0.747)a 0.715 (0.432–1.185)
CHESS
Score of 0 Ref. Ref. Ref. Ref.
Score of 1 or 2 0.959 (0.855–1.077) 0.916 (0.783–1.071) 0.882 (0.716–1.086) 0.709 (0.539–0.932)a
Score of 3 0.793 (0.653–0.963)a 0.906 (0.693–1.185) 0.517 (0.354–0.754)a 0.683 (0.422–1.106)
Score of 4 or 5 0.666(0.468–0.948)a 0.673 (0.396–1.144) 0.657 (0.318–1.356) 1.639 (0.727–3.695)
Activities of Daily Living 0.989 (0.979–0.998)a 0.975 (0.963–0.988)a 0.983 (0.964–1.002) 0.969 (0.945–0.994)a
Elixhauser/Other Comorbidities
Aphasia 0.564 (0.404–0.787)a 0.523 (0.313–0.903)a – –
Congestive Heart Failure 0.816 (0.720–0.925)a 0.804 (0.674–0.959)a – –
Hypertension, Uncomplicated 1.348 (1.213–1.497)a 1.105 (0.957–1.276) – –
Weight Loss 0.765 (0.622–0.942)a 0.767 (0.565–1.042) – –
Blood Loss Anemia 0.982 (0.709–1.361) 0.585 (0.348–0.982)a – –
Hemiplegia/Hemiparesis – – 1.581 (1.152–2.168)a 1.618 (1.075–2.435)a
Diabetes, Complicated – – 0.889 (0.615–1.284) 0.405 (0.215–0.766)a
Bladder Continence
Continent Ref. Ref. Ref. Ref.
Usually Continent 1.144 (0.963–1.359) 0.999 (0.789–1.265) 1.543 (1.108–2.149)a 0.994 (0.640–1.543)
Occasionally Incontinent 1.570 (1.311–1.881)a 1.359 (1.063–1.737)a 1.601 (1.153–2.224)a 1.510 (0.994–2.294)
Frequently Incontinent 1.406 (1.182–1.672)a 1.389 (1.097–1.760)a 2.011 (1.484–2.726)a 1.264 (0.846–1.888)
Incontinent 1.048 (0.835–1.315) 1.100 (0.791–1.531) 1.282 (0.902–1.822) 1.055 (0.652–1.708)
Indwelling Catheter 1.028 (0.864–1.222) 0.774 (0.600–0.998)a – –
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Table 4 Predictors of Type of Bladder Antimuscarinics Initiation, Stratified by Sex (Continued)
Females (n = 9322) Males (n = 3011)
New non-selective ER user
vs. new non-selective IR
user




user vs. new non-
selective IR user
New selective user vs.
New non-selective IR
user
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
No Bladder Continence Appliance or
Program
1.158 (1.002–1.339)a 0.917 (0.753–1.117) – –
Pads/Briefs Used – – 0.769 (0.602–0.982)a 1.271 (0.917–1.763)
Bowel Continence
Continent Ref. Ref. Ref. Ref.
Usually Continent 0.750 (0.626–0.899)a 0.940 (0.742–1.191) 0.754 (0.535–1.061) 0.954 (0.622–1.463)
Occasionally Incontinent 0.981 (0.786–1.224) 0.812 (0.597–1.104) 0.855 (0.581–1.258) 0.783 (0.469–1.309)
Frequently Incontinent 0.771 (0.633–0.938)a 0.640 (0.483–0.848)a 0.737 (0.525–1.036) 0.596 (0.371–0.958)a
Incontinent 0.656 (0.529–0.813)a 0.564 (0.409–0.778)a 0.742 (0.519–1.062) 0.560 (0.340–0.920)a
Bowel Elimination Pattern: Regular 0.962 (0.854–1.084) 0.846 (0.720–0.995)a – –
Urinary Tract Infection in Last 30 Days 1.123 (0.997–1.265) 1.254 (1.067–1.474)a – –
Gait
Unsteady Gait 1.156 (1.044–1.280)a 1.074 (0.935–1.234) – –
Fell in Past 30 days 1.153 (1.032–1.288)a 1.053 (0.904–1.226) 1.315 (1.077–1.607)a 1.063 (0.812–1.390)
Hip Fracture in Last 180 Days 1.297 (1.063–1.583)a 1.084 (0.811–1.449) – –
Other Fracture in Last 180 Days 1.230 (1.033–1.465)a 1.339 (1.059–1.694)a – –
Balance While Standing
Maintained position as required in test – – Ref. Ref.
Unsteady, but able to rebalance self
without physical support
– – 0.572 (0.370–0.885)a 0.806 (0.465–1.396)
Partial physical support during test or
stands but does not follow directions
for test
– – 0.766 (0.503–1.167) 0.879 (0.513–1.506)
Not able to attempt test without
physical help
– – 0.777 (0.500–1.208) 0.896 (0.506–1.588)
Balance While Sitting
Maintained position as required in test – – Ref. Ref.
Unsteady, but able to rebalance self
without physical support
– – 0.968 (0.719–1.302) 1.259 (0.871–1.819)
Partial physical support during test or
stands but does not follow directions
for test
– – 0.883 (0.662–1.178) 0.702 (0.463–1.064)
Not able to attempt test without
physical help
– – 0.650 (0.466–0.909)a 0.580 (0.356–0.945)a
Concomitant Medications
Calcium Channel Blockers 1.025 (0.917–1.145) 1.195 (1.031–1.386)a – –
Cognitive Enhancers 1.057 (0.939–1.191) 1.280 (1.091–1.501)a – –
Antiparkinson 0.891 (0.749–1.059) 1.334 (1.066–1.668)a 0.957 (0.727–1.259) 1.462 (1.039–2.056)a
Antipsychotics 0.500 (0.440–0.567)a 0.875 (0.735–1.043) 0.440 (0.349–0.556)a 0.891 (0.657–1.207)
Antivertigo 0.296 (0.256–0.342)a 0.763 (0.624–0.932)a 0.174 (0.127–0.237)a 0.642 (0.430–0.960)a
Anxiolytic Sedative or Hypnotic Agent 0.671 (0.580–0.775)a 1.070 (0.879–1.302) 0.723 (0.548–0.952)a 0.911 (0.625–1.327)
Antidepressant 0.585 (0.526–0.651)a 1.326 (1.145–1.535)a 0.617 (0.508–0.952)a 1.313 (1.012–1.704)a
ARB 1.066 (0.913–1.244) 1.340 (1.103–1.629)a – –
Alpha Blockers 0.763 (0.622–0.935)a 0.893 (0.678–1.176) 1.286 (1.067–1.549)a 1.752 (1.372–2.237)a
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catheter) were found to be significant predictors of type of
BAM initiation in the combined model specification, but in
model specifications stratified by sex the use of pads/briefs
was predictive of type of BAM initiation in males and use of
indwelling catheter was predictive of type of BAM initiation
in females. This suggests that there is little discernable influ-
ence of non-pharmacological continence management tech-
niques on BAM prescribing practices, or at least that other
factors are weighted more heavily in prescribing decisions.
Additionally, taking benzodiazepines concomitantly
was a significant predictor of type of BAM initiation in
both the combined model, and the sex-stratified model.
Furthermore, in both the models, those with moderate
to severe cognitive impairment were less likely to have
been initiated on selective BAMs. This is of note, keep-
ing in mind that selective BAMs may have a less harmful
adverse event profile in comparison to non-selective
BAMs. Severity of cognitive impairment does not seem
to be associated with type of BAM initiation when
pharmacological treatment options were considered.
The findings also indicate that prescribing preferences
for type of BAM when BAM is initiated in nursing home
patients may be, in part, driven by geography. Prescrip-
tions for non-selective IR BAM were more likely than
prescriptions for non-selective ER BAM and selective
BAM in the Midwest region for both sexes, when com-
pared to other regions. There is some evidence to sug-
gest that prescribing patterns differ by geographic
location for use of certain classes of medications (e.g.,
antipsychotic medications) in nursing home populations
[53], though this has not been previously studied for
BAM. One possible explanation for this geographic vari-
ation is range Pharmacy Benefit Management penetra-
tion across the regions, which could selectively influence
type of BAM initiation by formulary structure. Previous
research by Smith et al. has shown that Black nursing
home residents are more likely to be at nursing homes
that are greatly understaffed relative to the acuity profile
of their residents [54]. This is important for conditions
like urinary incontinence, where behavioral interventions
need individual attention from the staff, and lacking this,
pharmacological interventions may be relied upon. Svar-
stad et al. showed that treatment cultures at various nurs-
ing homes influence their efforts to reduce the use of
psychotropic medications [55]. While these are not the
class of drugs under discussion in our paper, it can be rea-
sonably inferred that treatment cultures would influence
the use of BAMs as well, especially considering the fact
that they are adjunct therapy to be used in addition to
other behavioral interventions. Although we did not ob-
serve any particular racial variation in the initiation by
type of BAMs, differences in treatment cultures and racial
disparities in nursing home care in the Midwest region
may have driven the geographic variation.
Some limitations of the study included the use of
claims data to identify users of these medications.
Claims data are not recorded for research purposes, and
therefore there could be miscoding errors. In addition,
pharmacy claims lack the information on the diagnosis
driving the indication; considering that some of the
medications included in our study could be used for
other purposes there is some room for misclassification.
This is, however, to our knowledge, the first study that
evaluates predictors of the initiation of BAM therapy by
type, and provides insight on prescribing variability by
various factors that could be used to further investigate
appropriateness of medication utilization and conduct
comparative effectiveness studies. There are also limita-
tions regarding the extent of the analysis; namely, type
of provider (e.g., MD or NP) prescribing BAM was not
examined and transdermal BAM formulations were ex-
cluded form the analysis. Lastly, BAM formulations
newer to the market (and therefore not summarized in
Additional file 1: Table S1) may not have achieved wide-
spread dissemination prior to the study period (e.g., ex-
tended release trospium was brought to market in 2007
at the beginning of the study period), and other changes
in prescribing trends may have occurred in the time fol-
lowing the study period. Considering the descriptive na-
ture of the current study, it would be difficult to make
further inferences about the associations noted in our
results. Certainly, this study raises important questions,
Table 4 Predictors of Type of Bladder Antimuscarinics Initiation, Stratified by Sex (Continued)
Females (n = 9322) Males (n = 3011)
New non-selective ER user
vs. new non-selective IR
user




user vs. new non-
selective IR user
New selective user vs.
New non-selective IR
user
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Anticonvulsant 0.733 (0.650–0.826)a 0.941 (0.801–1.106) 0.755 (0.607–0.940)a 0.965 (0.726–1.283)
Vasodilators 0.609 (0.526–0.705)a 1.071 (0.879–1.306) 0.508 (0.390–0.663)a 0.912 (0.641–1.297)
Benzodiazepines 1.968 (1.099–3.526)a 2.232 (1.085–4.592)a 3.592 (1.331–9.690)a Omission (Not enough
data)
Anticholinergic Burden Score 1.455 (1.418–1.493)a 0.798 (0.767–0.830)a 1.578 (1.501–1.659)a 0.846 (0.786–0.911)a
aIndicates statistical significance
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Table 5 Predictors of Type of Bladder Antimuscarinics Initiation Using Imputed Values in All New Users (n = 12,899)
New non-selective ER user vs.
New non-selective IR user
New selective user vs. new
non-selective IR user
OR (95% CI) OR (95% CI)
Age Group
65 to 74 Ref. Ref.
75 to 84 1.019 (0.900–1.153) 0.956 (0.808–1.130)
85 and Older 0.863 (0.760–0.980)a 0.884 (0.745–1.050)
Female 1.279 (1.145–1.428)a 1.324 (1.139–1.539)a
Race
White Ref. Ref.
Black 1.269 (1.078–1.494)a 0.925 (0.734–1.165)
Other Race 1.019 (0.789–1.316) 1.269 (0.898–1.793)
Nursing Home Region
Midwest Ref. Ref.
Northeast 0.627 (0.561–0.700)a 0.575 (0.489–0.675)a
South 0.651 (0.587–0.723) 1.043 (0.911–1.193)
West 0.868 (0.727–1.036) 0.630 (0.483–0.821)a
Body Mass Index
Underweight 0.785 (0.670–0.919)a 0.684 (0.539–0.869)a
Normal Ref. Ref.
Overweight 1.085 (0.978–1.204) 1.198 (1.042–1.378)a
Obese 1.322 (1.178–1.483)a 1.342 (1.149–1.567)a
Cognitive Performance Score
Intact Ref. Ref.
Borderline intact/Mild Impairment 1.006 (0.896–1.131) 1.071 (0.916–1.252)
Moderate impairment 0.997 (0.876–1.134) 0.943 (0.792–1.123)
Moderate-severe/Severe/Very Severe impairment 0.526 (0.440–0.628)a 0.527 (0.406–0.683)a
CHESS
Score of 0 Ref. Ref.
Score of 1 or 2 0.928 (0.840–1.025) 0.852 (0.746–0.974)a
Score of 3 0.729 (0.615–0.865)a 0.820 (0.650–1.034)
Score of 4 or 5 0.650 (0.475–0.890)a 0.811 (0.527–1.248
Activities of Daily Living 0.989 (0.980–0.997)a 0.976 (0.965–0.987)a
Elixhauser/Other Comorbidities
Aphasia 0.605 (0.457–0.801)a 0.574 (0.373–0.882)a
Congestive Heart Failure 0.839 (0.755–0.934)a 0.865 (0.747–1.002)
Hypertension, Uncomplicated 1.295 (1.184–1.416)a 1.054 (0.933–1.191)
Weight Loss 0.753 (0.635–0.893)a 0.745 (0.580–0.958)a
Bladder Continence
Continent Ref. Ref.
Usually Continent 1.244 (1.076–1.438)a 1.099 (0.903–1.337)
Occasionally Incontinent 1.586 (1.370–1.837)a 1.494 (1.228–1.819)a
Frequently Incontinent 1.538 (1.343–1.761)a 1.517 (1.263–1.823)a
Incontinent 1.083 (0.915–1.281) 1.240 (0.973–1.582)
No Bladder Continence Appliance or Program 1.214 (1.081–1.363)a 0.997 (0.852–1.166)
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including the predictive effect on BAM initiation with
benzodiazepine use, or the noted geographic variability.
However, further investigations would be necessary to
completely understand and untangle these observations.
Conclusions
Our investigation reveals important predictors of different
BAM initiation in long-term care and describes differences
between women and men. Our findings can be used to
guide study design to develop and inform appropriate strat-
egies to control for confounding in comparative effective-
ness studies of different BAM; these are necessary steps for
informing the clinical decision making process for BAM
therapy selection in the nursing homes population and can
be used to further develop strategies for targeted interven-
tions to improve medication use for the treatment of urin-
ary incontinence by addressing modifiable factors
associated with BAM initiation.
Table 5 Predictors of Type of Bladder Antimuscarinics Initiation Using Imputed Values in All New Users (n = 12,899) (Continued)
New non-selective ER user vs.
New non-selective IR user
New selective user vs. new
non-selective IR user
OR (95% CI) OR (95% CI)
Bowel Continence
Continent Ref. Ref.
Usually Continent 0.729 (0.624–0.852)a 0.943 (0.771–1.153)
Occasionally Incontinent 0.901 (0.748–1.086) 0.768 (0.593–0.994)a
Frequently Incontinent 0.750 (0.636–0.885)a 0.641 (0.508–0.809)a
Incontinent 0.678 (0.568–0.808)a 0.583 (0.451–0.753)a
Urinary Tract Infection in Last 30 Days 1.104 (0.995–1.225) 1.168 (1.015–1.344)a
Gait
Unsteady Gait 1.019 (0.894–1.162) 0.939 (0.784–1.124)
Fell in Past 30 days 1.032 (0.904–1.177) 0.890 (0.739–1.071)
Hip Fracture in Last 180 Days 0.825 (0.705–0.966)a 0.679 (0.538–0.857)a
Other Fracture in Last 180 Days 1.131 (1.037–1.235)a 1.025 (0.911–1.155)
Balance While Sitting
Maintained position as required in test Ref. Ref.
Unsteady, but able to rebalance self without
physical support
1.183 (1.076–1.300)a 1.064 (0.935–1.210)
Partial physical support during test or stands but
does not follow directions for test
0.252 (1.049–1.494)a 1.057 (0.818–1.365)
Not able to attempt test without physical help 1.250 (1.065–1.467)a 1.348 (1.090–1.668)a
Concomitant Medications
Calcium Channel Blockers 1.029 (0.935–1.134) 1.156 (1.016–1.315)a
Cognitive Enhancers 1.049 (1.044–1.369)a 1.196 (1.044–1.369)a
Antiparkinson 0.902 (0.782–1.040) 1.354 (1.129–1.625)a
Antipsychotics 0.472 (0.423–0.526)a 0.873 (0.753–1.012)
Antivertigo 0.267 (0.235–0.303)a 0.729 (0.612–0.867)a
Anxiolytic Sedative or Hypnotic Agent 0.671 (0.592–0.760)a 1.025 (0.865–1.214)
Antidepressant 0.602 (0.549–0.660)a 1.301 (1.148–1.474)a
ARB 1.004 (0.874–1.152) 1.305 (1.097–1.552)a
Alpha Blockers 1.038 (0.909–1.186) 1.327 (1.116–1.579)a
Anticonvulsant 0.727 (0.656–0.806)a 0.930 (0.810–1.067)
Vasodilators 0.584 (0.515–0.662)a 0.990 (0.836–1.172)
Benzodiazepines 2.058 (1.251–3.387)a 1.885 (0.993–3.578)
Anticholinergic Burden Score 1.478 (1.445–1.511)a 0.807 (0.780–0.835)a
aIndicates statistical significance
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Table 6 Predictors of Type of Bladder Antimuscarinics Initiation Using Imputed Values, Stratified by Sex
Females (n = 9732) Males (n = 3167)
New non-selective ER user
vs. new non-selective IR
user




user vs. new non-
selective IR user
New selective user vs.
New non-selective IR
user
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Race
White – – Ref. Ref.
Black – – 1.732 (1.301–2.305)a 1.020 (0.673–1.547)
Other Race – – 1.092 (0.692–1.723) 1.769 (1.004–3.118)a
Nursing Home Region
Midwest Ref. Ref. Ref. Ref.
Northeast 0.688 (0.606–0.781)a 0.604 (0.503–0.727)a 0.426 (0.337–0.539)a 0.478 (0.340–0.672)a
South 0.709 (0.630–0.797)a 1.047 (0.897–1.222) 0.534 (0.428–0.667)a 1.101 (0.834–1.454)
West 0.857 (0.698–1.053) 0.660 (0.483–0.903)a 0.912 (0.651–1.278) 0.603 (0.366–0.993)a
Body Mass Index
Underweight 0.781 (0.656–0.931)a 0.727 (0.561–0.943)a 0.816 (0.570–1.170) 0.442 (0.234–0.837)a
Normal Ref. Ref. Ref. Ref.
Overweight 1.130 (1.002–1.276)a 1.184 (1.006–1.394)a 0.982 (0.795–1.211) 1.365 (1.038–1.796)a
Obese 1.364 (1.200–1.551)a 1.347 (1.131–1.605)a 1.394 (1.090–1.783)a 1.654 (1.201–2.278)a
Cognitive Performance Score
Intact Ref. Ref. Ref. Ref.
Borderline intact/Mild Impairment 1.008 (0.883–1.150) 1.061 (0.889–1.267) 0.960 (0.747–1.235) 1.016 (0.729–1.417)
Moderate impairment 0.978 (0.845–1.132) 0.891 (0.730–1.088) 1.009 (0.772–1.320) 1.018 (0.711–1.457)
Moderate-severe/Severe/Very Severe impairment 0.508 (0.414–0.624)a 0.445 (0.328–0.603)a 0.509 (0.358–0.723)a 0.689 (0.424–1.119)
CHESS
Score of 0 Ref. Ref. Ref. Ref.
Score of 1 or 2 0.951 (0.849–1.066) 0.906 (0.776–1.057) 0.871 (0.710–1.069) 0.727 (0.557–0.949)a
Score of 3 0.788 (0.650–0.956)a 0.882 (0.675–1.152) 0.525 (0.361–0.764)a 0.684 (0.423–1.103)
Score of 4 or 5 0.648 (0.457–0.920)a 0.691 (0.412–1.159) 0.612 (0.299–1.252) 1.431 (0.639–3.204)
Activities of Daily Living 0.990 (0.980–0.999)a 0.975 (0.963–0.988)a 0.984 (0.965–1.002) 0.972 (0.948–0.997)a
Elixhauser/Other Comorbidities
Aphasia 0.574 (0.416–0.790)a 0.496 (0.293–0.840)a – –
Congestive Heart Failure 0.814 (0.720–0.920)a 0.811 (0.683–0.963)a – –
Hypertension, Uncomplicated 1.348 (1.216–1.494)a 1.108 (0.962–1.275) – –
Weight Loss 0.752 (0.614–0.920)a 0.746 (0.552–1.007) – –
Blood Loss Anemia 0.987 (0.718–1.357) 0.596 (0.359–0.988)a – –
Hemiplegia/Hemiparesis – – 1.547 (1.139–2.100)a 1.598 (1.075–2.376)a
Diabetes, Complicated – – 0.940 (0.657–1.344) 0.454 (0.250–0.826)a
Bladder Continence
Continent Ref. Ref. Ref. Ref.
Usually Continent 1.157 (0.978–1.370) 1.028 (0.816–1.295) 1.476 (1.070–2.035)a 0.988 (0.645–1.512)
Occasionally Incontinent 1.536 (1.288–1.833)a 1.346 (1.058–1.712)a 1.663 (1.295–2.295)a 1.442 (0.957–2.174)
Frequently Incontinent 1.400 (1.181–1.659)a 1.403 (1.113–1.770)a 2.032 (1.509–2.737)a 1.269 (0.859–1.875)
Incontinent 1.018 (0.815–1.270) 1.120 (0.812–1.543) 1.274 (0.908–1.786) 0.987 (0.620–1.571)
Indwelling Catheter 1.006 (0.849–1.191) 0.769 (0.601–0.985)a – –
Pads/Briefs Used – – 0.793 (0.625–1.006) 1.286 (0.935–1.767)
No Bladder Continence Appliance or Program 1.156 (1.003–1.333)a 0.935 (0.771–1.134) – –
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Table 6 Predictors of Type of Bladder Antimuscarinics Initiation Using Imputed Values, Stratified by Sex (Continued)
Females (n = 9732) Males (n = 3167)
New non-selective ER user
vs. new non-selective IR
user




user vs. new non-
selective IR user
New selective user vs.
New non-selective IR
user
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Bowel Continence
Continent Ref. Ref. Ref. Ref.
Usually Continent 0.741 (0.620–0.885)a 0.934 (0.740–1.178) 0.719 (0.515–1.004) 0.977 (0.647–1.475)
Occasionally Incontinent 0.935 (0.753–1.161) 0.779 (0.576–1.055) 0.832 (0.569–1.218) 0.764 (0.460–1.269)
Frequently Incontinent 0.766 (0.631–0.929)a 0.649 (0.493–0.854)a 0.728 (0.522–1.014) 0.595 (0.374–0.945)a
Incontinent 0.659 (0.535–0.813)a 0.575 (0.421–0.785)a 0.731 (0.517–1.033) 0.569 (0.352–0.921)a
Bowel Elimination Pattern: Regular 0.977 (0.869–1.098) 0.862 (0.736–1.010) – –
Urinary Tract Infection in Last 30 Days 1.118 (0.996–1.256) 1.217 (1.039–1.426)a – –
Balance While Standing
Maintained position as required in test – – Ref. Ref.
Unsteady, but able to rebalance self without
physical support
– – 0.591 (0.387–0.904)a 0.738 (0.436–1.248)
Partial physical support during test or stands
but does not follow directions for test
– – 0.769 (0.511–1.157) 0.827 (0.495–1.381)
Not able to attempt test without physical help – – 0.786 (0.512–1.206) 0.838 (0.486–1.445)
Balance While Sitting
Maintained position as required in test – – Ref. Ref.
Unsteady, but able to rebalance self without
physical support
– – 0.918 (0.688–1.224) 1.182 (0.827–1.690)
Partial physical support during test or stands but
does not follow directions for test
– – 0.878 (0.664–1.162) 0.679 (0.454–1.017)
Not able to attempt test without physical help – – 0.601 (0.434–0.831)a 0.532 (0.331–0.855)a
Gait
Unsteady Gait 1.147 (1.038–1.267)a 1.087 (0.949–1.245) – –
Fell in Past 30 days 1.137 (1.020–1.266)a 1.050 (0.906–1.219) 1.349 (1.10–1.639)a 1.071 (0.825–1.391)
Hip Fracture in Last 180 Days 1.277 (1.050–1.554)a 1.117 (0.842–1.482) – –
Other Fracture in Last 180 Days 1.228 (1.035–1.457)a 1.331 (1.058–1.673)a – –
Concomitant Medications
Calcium Channel Blockers 1.035 (0.929–1.154) 1.177 (1.018–1.361)a – –
Cognitive Enhancers 1.079 (0.960–1.212) 1.282 (1.097–1.499)a – –
Antiparkinson 0.894 (0.755–1.060) 1.327 (1.066–1.652)a 0.968 (0.741–1.266) 1.416 (1.014–1.978)a
Antipsychotics 0.490 (0.433–0.555)a 0.878 (0.722–1.019) 0.455 (0.363–0.571)a 0.928 (0.692–1.245)
Antivertigo 0.292 (0.254–0.337)a 0.791 (0.650–0.962)a 0.179 (0.132–0.242)a 0.573 (0.385–0.853)a
Anxiolytic Sedative or Hypnotic Agent 0.668 (0.580–0.770)a 1.074 (0.887–1.301) 0.710 (0.543–0.928)a 0.881 (0.609–1.275)
Antidepressant 0.593 (0.534–0.658)a 1.311 (1.136–1.513)a 0.598 (0.494–0.723)a 1.277 (0.991–1.646)
ARB 1.045 (0.898–1.216) 1.337 (1.104–1.619)a – –
Alpha Blockers 0.778 (0.637–0.950)a 0.921 (0.703–1.206) 1.288 (1.074–1.544)a 1.785 (1.408–2.264)a
Anticonvulsant 0.740 (0.658–0.833)a 0.931 (0.794–1.091) 0.750 (0.607–0.927)a 0.970 (0.737–1.277)
Vasodilators 0.600 (0.520–0.693)a 1.043 (0.859–1.268) 0.516 (0.398–0.669)a 0.875 (0.618–1.239)
Benzodiazepines 1.821 (1.022–3.245)a 2.327 (1.156–4.685)a 3.108 (1.168–8.269)a 0.573 (0.068–4.790)
Anticholinergic Burden Score 1.458 (1.422–1.495)a 0.796 (0.766–0.828)a 1.569 (1.495–1.647)a 0.846 (0.787–0.909)a
aIndicates statistical significance
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Additional file
Additional file 1: Table S1. Bladder Antimuscarinics- Important Drug
Characteristics and Relevant Clinical Information. This supplementary
table contains a summary of the important strengths and weaknesses of
each bladder antimuscarinic medication included within this study, as
well as a description of each medications’ M1-M5 receptor affinity.
(DOCX 24 kb)
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